[Case report: RAEB in a patient with rheumatoid arthritis treated with methotrexate and infliximab]. 2006

Giuseppe D'Alessandro, and Maria Rosaria Bianco, and Spiridion Politis, and Celestino Ferrandina, and Giuseppe Rossi, and Emanuele Altomare
II Medicina Interna Universitaria, Azienda Ospedaliero Universitaria Ospedali Riuniti, 71100 Foggia. meduni@unifg.it

Anti TNF-alpha drugs seem to be the new frontier of Rheumatoid Arthritis (RA) therapy. The association infliximab methotrexate has been approved for the treatment of RA not responding to the classic therapy, but the short clinical experience in using antiTNF-alpha molecules brings to segnalation of new risks or adverse events. We describe a case of a patient, treated for many years with classic RA therapy, which developed a refractory anemia after treatment with association infliximab-methotrexate.

UI MeSH Term Description Entries
D008727 Methotrexate An antineoplastic antimetabolite with immunosuppressant properties. It is an inhibitor of TETRAHYDROFOLATE DEHYDROGENASE and prevents the formation of tetrahydrofolate, necessary for synthesis of thymidylate, an essential component of DNA. Amethopterin,Methotrexate Hydrate,Methotrexate Sodium,Methotrexate, (D)-Isomer,Methotrexate, (DL)-Isomer,Methotrexate, Dicesium Salt,Methotrexate, Disodium Salt,Methotrexate, Sodium Salt,Mexate,Dicesium Salt Methotrexate,Hydrate, Methotrexate,Sodium, Methotrexate
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001853 Bone Marrow The soft tissue filling the cavities of bones. Bone marrow exists in two types, yellow and red. Yellow marrow is found in the large cavities of large bones and consists mostly of fat cells and a few primitive blood cells. Red marrow is a hematopoietic tissue and is the site of production of erythrocytes and granular leukocytes. Bone marrow is made up of a framework of connective tissue containing branching fibers with the frame being filled with marrow cells. Marrow,Red Marrow,Yellow Marrow,Marrow, Bone,Marrow, Red,Marrow, Yellow
D004359 Drug Therapy, Combination Therapy with two or more separate preparations given for a combined effect. Combination Chemotherapy,Polychemotherapy,Chemotherapy, Combination,Combination Drug Therapy,Drug Polytherapy,Therapy, Combination Drug,Chemotherapies, Combination,Combination Chemotherapies,Combination Drug Therapies,Drug Polytherapies,Drug Therapies, Combination,Polychemotherapies,Polytherapies, Drug,Polytherapy, Drug,Therapies, Combination Drug
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000069285 Infliximab A chimeric monoclonal antibody to TNF-ALPHA that is used in the treatment of RHEUMATOID ARTHRITIS; ANKYLOSING SPONDYLITIS; PSORIATIC ARTHRITIS and CROHN'S DISEASE. Inflectra,Infliximab-abda,Infliximab-dyyb,MAb cA2,Monoclonal Antibody cA2,Remicade,Renflexis,Antibody cA2, Monoclonal,Infliximab abda,Infliximab dyyb,cA2, Monoclonal Antibody
D000754 Anemia, Refractory, with Excess of Blasts Chronic refractory anemia with granulocytopenia, and/or thrombocytopenia. Myeloblasts and progranulocytes constitute 5 to 40 percent of the nucleated marrow cells. Leukemia, Smoldering,RAEB,RAEM,Refractory Anemia with Excess of Blasts,Leukemia, Smouldering,Leukemias, Smoldering,Smoldering Leukemia,Smoldering Leukemias,Smouldering Leukemia
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D001172 Arthritis, Rheumatoid A chronic systemic disease, primarily of the joints, marked by inflammatory changes in the synovial membranes and articular structures, widespread fibrinoid degeneration of the collagen fibers in mesenchymal tissues, and by atrophy and rarefaction of bony structures. Etiology is unknown, but autoimmune mechanisms have been implicated. Rheumatoid Arthritis

Related Publications

Giuseppe D'Alessandro, and Maria Rosaria Bianco, and Spiridion Politis, and Celestino Ferrandina, and Giuseppe Rossi, and Emanuele Altomare
January 2016, Reumatizam,
Giuseppe D'Alessandro, and Maria Rosaria Bianco, and Spiridion Politis, and Celestino Ferrandina, and Giuseppe Rossi, and Emanuele Altomare
January 2023, Medicine,
Giuseppe D'Alessandro, and Maria Rosaria Bianco, and Spiridion Politis, and Celestino Ferrandina, and Giuseppe Rossi, and Emanuele Altomare
July 2008, Clinical and experimental dermatology,
Giuseppe D'Alessandro, and Maria Rosaria Bianco, and Spiridion Politis, and Celestino Ferrandina, and Giuseppe Rossi, and Emanuele Altomare
July 2002, The Journal of rheumatology,
Giuseppe D'Alessandro, and Maria Rosaria Bianco, and Spiridion Politis, and Celestino Ferrandina, and Giuseppe Rossi, and Emanuele Altomare
January 2004, Clinical and experimental rheumatology,
Giuseppe D'Alessandro, and Maria Rosaria Bianco, and Spiridion Politis, and Celestino Ferrandina, and Giuseppe Rossi, and Emanuele Altomare
September 2004, Rheumatology (Oxford, England),
Giuseppe D'Alessandro, and Maria Rosaria Bianco, and Spiridion Politis, and Celestino Ferrandina, and Giuseppe Rossi, and Emanuele Altomare
January 2010, Internal medicine (Tokyo, Japan),
Giuseppe D'Alessandro, and Maria Rosaria Bianco, and Spiridion Politis, and Celestino Ferrandina, and Giuseppe Rossi, and Emanuele Altomare
January 2017, Mediators of inflammation,
Giuseppe D'Alessandro, and Maria Rosaria Bianco, and Spiridion Politis, and Celestino Ferrandina, and Giuseppe Rossi, and Emanuele Altomare
March 2015, BMC research notes,
Giuseppe D'Alessandro, and Maria Rosaria Bianco, and Spiridion Politis, and Celestino Ferrandina, and Giuseppe Rossi, and Emanuele Altomare
June 2003, Rheumatology (Oxford, England),
Copied contents to your clipboard!